PSA vs ZYME · rev $4.82B vs rev $76.3M
PSA (PSA) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
PSA (PSA) common stock.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
PSA currently screens at market cap $0. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the PSA and ZYME stock pages for the full models.
Not investment advice.